|

Liver Cancer Clinical Trials in San Antonio, TX

18 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsPhase 1/2<1 mi
FOG-001 in Locally Advanced or Metastatic Solid TumorsPhase 1/2<1 mi
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)Phase 2<1 mi
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentPhase 1<1 mi
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1<1 mi
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment—<1 mi
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaPhase 1<1 mi
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple MyelomaPhase 1<1 mi
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaPhase 1/2<1 mi
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma—<1 mi
IDOV-Immune for Advanced Solid TumorsPhase 1<1 mi
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisPhase 2<1 mi
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver ImpairmentPhase 1<1 mi
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgeryPhase 2<1 mi
A Study of ZW251 in Participants With Advanced Solid TumorsPhase 1<1 mi
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentPhase 1<1 mi
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsPhase 1<1 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 3<1 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.